American College of Rheumatology

The time of flare was significantly shorter in the placebo group compared to the baricitinib.

For safety, the proportions of patients with serious treatment-emergent adverse events in the second treatment period were similar between the treatment groups.

Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

The results show 88.1% of patients with rheumatoid arthritis in the study developed humoral immunogenicity.

A post hoc subgroup analysis compared TNFi-IR patients receiving upadacitinib 15 mg once daily in 3 Phase 3 clinical trials: SELECT-BEOYND, SELECT-CHOICE, and SELECT-COMPARE.

There were no significant safety issues in the group of patients treated with secukinumab for more than 3 years.

The results also show substantial medication substitution across prescription drug classes related to medical cannabis use.

Low levels of disease activity were achieved and increased throughout the study.

The median time-to-remission was longer for women compared to men.

Individuals who were socially isolated at time of fracture had significantly worse function, ability to participate in social roles, and depression time of fracture.

Hamilton and his team aim to reduce intensive and often unnecessary screening, including weekly fetal cardiac ultrasounds, via autoantibody identification.

The number of autoantibodies and congenital heart block pregnancies expanded to approximately 30 different autoantibodies to different targets near term.

The results show improvements in RAPID3, pain, fatigue, and morning stiffness at weeks 8 and 12 among patients treated with upadacitinib.

Patients with ankylosing spondylitis generally had more favorable outcomes compared to those with psoriasis or psoriatic arthritis.

In data presented during ACR, investigators find peresolimab could be an effective treatment for adult patients with rheumatoid arthritis.

Patients who are treated with B cell depletion therapies show that their B cell count at time of vaccination can impact their COVID-19 antibody response.

An assessment of a rheumatic disease cohort shows Spike protein antibody response is significantly decreased in vaccinated patients, and may vary by treatment.

Lower health literacy has been found to be associated with worsened health outcomes for patients with systemic lupus erythematosus (SLE).

Fetal deaths associated with the rheumatic disease have been on the decline, but increased risks persist nonetheless.

Alopecia and nausea risk may be more easily identified in patients initiating methotrexate for rheumatoid arthritis.

A study presented at ACR 2021 found that CBD had no significant effect on pain intensity in patients with hand osteoarthritis or psoriatic arthritis.

An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.

Interim data from a post-marketing analysis suggest a boxed label warning for the drug in 2019 may have limited high-risk patients taking the biologic therapy.

A cross-sectional analysis suggests patients with worse social risk scores are significantly more likely to be impacted by juvenile idiopathic arthritis.

This study shows that many patients with rheumatoid arthritis can use a dose lower than 1000mg and still see results.

With the popularity of CBD growing in Denmark, Jonathan Vela, MD, examined the effectiveness of CBD treatment on hand osteoarthritis and psoriatic arthritis.

More data from ACR 2021 evidences the risk of minimal response to mRNA vaccines in autoimmune disorder patients on rituximab.